U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Liposarcoma

MedGen UID:
1719796
•Concept ID:
C5239059
•
Neoplastic Process

Definition

A liposarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Liposarcoma

Professional guidelines

PubMed

Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat 2022;45(9):525-543. Epub 2022 May 24 doi: 10.1159/000524939. PMID: 35609512
Early treatment-related neutropenia predicts response to palbociclib.
McAndrew NP, Dickson MA, Clark AS, Troxel AB, O'Hara MH, Colameco C, Gallager M, Gramlich K, Zafman K, Vaughn D, Schwartz GK, O'Dwyer PJ, DeMichele A
Br J Cancer 2020 Sep;123(6):912-918. Epub 2020 Jul 9 doi: 10.1038/s41416-020-0967-7. PMID: 32641862Free PMC Article
Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
Emambux S, Italiano A
Expert Opin Pharmacother 2017 Jun;18(8):819-824. doi: 10.1080/14656566.2017.1326908. PMID: 28468516

Recent clinical studies

Etiology

Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma.
Wozniak A, Boeckx B, Modave E, Weaver A, Lambrechts D, Littlefield BA, Schöffski P
Clin Cancer Res 2021 Jun 1;27(11):3106-3115. Epub 2021 Apr 1 doi: 10.1158/1078-0432.CCR-20-4315. PMID: 33795257
Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
Langmans C, Cornillie J, van Cann T, Wozniak A, Hompes D, Sciot R, Debiec-Rychter M, Vandenbempt I, Schöffski P
Oncol Res Treat 2019;42(7-8):396-404. Epub 2019 Jun 6 doi: 10.1159/000500608. PMID: 31170709
Thoracic Liposarcoma In An End Stage Renal Disease Patient.
Ishtiaq R, Naeem A, Ratnani I
J Ayub Med Coll Abbottabad 2019 Apr-Jun;31(2):286-289. PMID: 31094134
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR
Lancet 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10 doi: 10.1016/S0140-6736(15)01283-0. PMID: 26874885
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR
J Clin Oncol 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14 doi: 10.1200/JCO.2015.62.4734. PMID: 26371143Free PMC Article

Diagnosis

Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat 2022;45(9):525-543. Epub 2022 May 24 doi: 10.1159/000524939. PMID: 35609512
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia S
Future Oncol 2021 Aug;17(22):2923-2939. Epub 2021 Apr 15 doi: 10.2217/fon-2021-0284. PMID: 33855868Free PMC Article
Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma.
Wozniak A, Boeckx B, Modave E, Weaver A, Lambrechts D, Littlefield BA, Schöffski P
Clin Cancer Res 2021 Jun 1;27(11):3106-3115. Epub 2021 Apr 1 doi: 10.1158/1078-0432.CCR-20-4315. PMID: 33795257
Dedifferentiated Liposarcoma: Systemic Therapy Options.
Gahvari Z, Parkes A
Curr Treat Options Oncol 2020 Feb 5;21(2):15. doi: 10.1007/s11864-020-0705-7. PMID: 32026050
Thoracic Liposarcoma In An End Stage Renal Disease Patient.
Ishtiaq R, Naeem A, Ratnani I
J Ayub Med Coll Abbottabad 2019 Apr-Jun;31(2):286-289. PMID: 31094134

Therapy

Pharmacotherapy for liposarcoma: current and emerging synthetic treatments.
Chamberlain F, Benson C, Thway K, Huang P, Jones RL, Gennatas S
Future Oncol 2021 Jul;17(20):2659-2670. Epub 2021 Apr 21 doi: 10.2217/fon-2020-1092. PMID: 33880964
Dedifferentiated Liposarcoma: Systemic Therapy Options.
Gahvari Z, Parkes A
Curr Treat Options Oncol 2020 Feb 5;21(2):15. doi: 10.1007/s11864-020-0705-7. PMID: 32026050
Eribulin in advanced liposarcoma and leiomyosarcoma.
Setola E, Noujaim J, Benson C, Chawla S, Palmerini E, Jones RL
Expert Rev Anticancer Ther 2017 Aug;17(8):717-723. Epub 2017 Jun 28 doi: 10.1080/14737140.2017.1344098. PMID: 28621163
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR
Lancet 2016 Apr 16;387(10028):1629-37. Epub 2016 Feb 10 doi: 10.1016/S0140-6736(15)01283-0. PMID: 26874885
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR
J Clin Oncol 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14 doi: 10.1200/JCO.2015.62.4734. PMID: 26371143Free PMC Article

Prognosis

Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma.
Wozniak A, Boeckx B, Modave E, Weaver A, Lambrechts D, Littlefield BA, Schöffski P
Clin Cancer Res 2021 Jun 1;27(11):3106-3115. Epub 2021 Apr 1 doi: 10.1158/1078-0432.CCR-20-4315. PMID: 33795257
Dedifferentiated Liposarcoma: Systemic Therapy Options.
Gahvari Z, Parkes A
Curr Treat Options Oncol 2020 Feb 5;21(2):15. doi: 10.1007/s11864-020-0705-7. PMID: 32026050
Thoracic Liposarcoma In An End Stage Renal Disease Patient.
Ishtiaq R, Naeem A, Ratnani I
J Ayub Med Coll Abbottabad 2019 Apr-Jun;31(2):286-289. PMID: 31094134
Eribulin in advanced liposarcoma and leiomyosarcoma.
Setola E, Noujaim J, Benson C, Chawla S, Palmerini E, Jones RL
Expert Rev Anticancer Ther 2017 Aug;17(8):717-723. Epub 2017 Jun 28 doi: 10.1080/14737140.2017.1344098. PMID: 28621163
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR
J Clin Oncol 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14 doi: 10.1200/JCO.2015.62.4734. PMID: 26371143Free PMC Article

Clinical prediction guides

Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma.
Kim CG, Sim NS, Kim JE, Yun KH, Lee YH, Kim SH, Baek W, Han YD, Kim SK, Kim JH, Koh YW, Jung I, Shin SJ, Rha SY, Ahn JH, Kim HS
Clin Cancer Res 2022 Aug 2;28(15):3225-3234. doi: 10.1158/1078-0432.CCR-22-0518. PMID: 35583824
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
Wagner MJ, Zhang Y, Cranmer LD, Loggers ET, Black G, McDonnell S, Maxwell S, Johnson R, Moore R, Hermida de Viveiros P, Aicher L, Smythe KS, He Q, Jones RL, Pollack SM
Clin Cancer Res 2022 Jun 1;28(11):2306-2312. doi: 10.1158/1078-0432.CCR-22-0240. PMID: 35349638Free PMC Article
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia S
Future Oncol 2021 Aug;17(22):2923-2939. Epub 2021 Apr 15 doi: 10.2217/fon-2021-0284. PMID: 33855868Free PMC Article
Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma.
Wozniak A, Boeckx B, Modave E, Weaver A, Lambrechts D, Littlefield BA, Schöffski P
Clin Cancer Res 2021 Jun 1;27(11):3106-3115. Epub 2021 Apr 1 doi: 10.1158/1078-0432.CCR-20-4315. PMID: 33795257
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR
J Clin Oncol 2016 Mar 10;34(8):786-93. Epub 2015 Sep 14 doi: 10.1200/JCO.2015.62.4734. PMID: 26371143Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...